CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma

European Journal of Haematology

Volumn 89, Issue 4, 2012, Pages 350-355

  Nakamaki, Tsuyoshi ^a   Fukuchi, Kunihiko ^a   Nakashima, Hidetoshi ^a   Ariizumi, Hirotsugu ^a   Maeda, Takashi ^a   Saito, Bungo ^a   Yanagisawa, Kouji ^a   Tomoyasu, Shigeru ^a   Homma, Mayumi ^a   Shiozawa, Eisuke ^a   Yamochi Onizuka, Toshiko ^a   Ota, Hidekazu ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD20; Deletion; Diffuse large B cell lymphoma

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; B CELL LYMPHOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEATH; FEMALE; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MOUSE; NEEDLE BIOPSY; NONHUMAN; PHENOTYPE; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SCID MOUSE; TREATMENT OUTCOME;

AGED; ANTIGENS, CD20; FEMALE; GENE DELETION; HUMANS; KARYOTYPING; POLYMERASE CHAIN REACTION;

EID: 84866348369     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01838.x     Document Type: Article

References (15)

1. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93.
2. Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci 2009;100:54-61.
3. Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH, Connors JM, Chhanabhai M, Brooks-Wilson A, Gascoyne RD. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009;94:423-7.
4. Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, Naoe T. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 2009;390:48-53.
5. Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Leuk Res 2009;33:792-7.
6. Terui Y, Mishima Y, Sugimura N, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009;15:2523-30.
7. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-90.
8. Berglund M, Enblad G, Flordal E, et al. Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. Mod Pathol 2002;15:807-16.
9. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009;113:3773-80.
10. Wu D, Wood BL, Dorer R, Fromm JR. "Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. Am J Clin Pathol 2010;134:258-65.
11. Miletic AV, Anzelon-Mills AN, Mills DM, Omori SA, Pedersen IM, Shin DM, Ravetch JV, Bolland S, Morse HC 3rd, Rickert RC. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med 2010;207:2407-20.
12. Gupta P, Goldenberg DM, Rossi EA, Chang CH. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010;116:3258-67.
13. Liang Y, Tedder TF. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 2001;72:119-27.
14. Donato JL, Ko J, Kutok JL, Cheng T, Shirakawa T, Mao XQ, Beach D, Scadden DT, Sayegh MH, Adra CN. Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest 2002;109:51-8.
15. Xu H, Yan Y, Williams MS, Carey GB, Yang J, Li H, Zhang GX, Rostami A. MS4a4B, a CD20 homologue in T cells, inhibits T cell propagation by modulation of cell cycle. PLoS ONE 2010;5:e13780.